Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
crispr
5
×
deals
5
×
life sciences
national blog main
boston blog main
editas medicine
national top stories
san francisco blog main
boston top stories
cancer
clinical trials
national
novartis
san francisco top stories
startups
abbvie
allergan
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
crispr therapeutics
detroit blog main
detroit top stories
europe blog main
fda
indiana blog main
indiana top stories
investing
ipo
medical devices
new york blog main
new york top stories
pfizer
raleigh-durham blog main
raleigh-durham top stories
rare diseases
san diego blog main
san diego top stories
seattle blog main
What
bio
car
crispr
develop
gene
medicines
roundup
abbvie
access
acquisitions
advanced
alliance
announced
available
bails
based
big
biosciences
biotech
brand
bridgebio
capacity
capital
cas
cell
ceo
cheaper
collabs
consolidation
covid
daniel
deal
diagnostics
drugs
editas
editing
emerges
exits
expects
experimental
Language
unset
5
×
Current search:
crispr
×
unset
×
deals
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More